Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
Commentary

Rising Stimulant Overdoses Among Young People in the United States

Scott E. Hadland and Brandon D.L. Marshall
Pediatrics January 2021, 147 (1) e2020031526; DOI: https://doi.org/10.1542/peds.2020-031526
Scott E. Hadland
aDepartment of Pediatrics, Boston Medical Center, Boston, Massachusetts;
bDivision of General Pediatrics, Department of Pediatrics, School of Medicine, Boston University, Boston, Massachusetts; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brandon D.L. Marshall
cDepartment of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • Comments
Loading
Download PDF

Although commonly described as an opioid crisis, the drug overdose epidemic in the United States increasingly involves use of substances other than opioids.1,2 In this issue of Pediatrics, Roehler et al3 describe a concerning rise in overdoses among children, adolescents, and young adults related to stimulants such as cocaine, methamphetamine, and prescription drugs (including those commonly used to treat attention deficient/hyperactivity disorder).

Drawing on 2016–2019 surveillance data from a plurality of US emergency departments across 47 states, the authors found that whereas visits for drug overdoses rose only slightly among children <15 and remained unchanged in adolescents and young adults 15 to 24, visits for stimulant overdoses increased across all ages. Specifically, over each quarter between April 2016 and September 2019, stimulant overdose visits among young people aged 0 to 10, 11 to 14, and 15 to 24 years increased by 3%, 4%, and 2%, respectively.

These findings mirror other recent national drug overdose trends. Although the overall US overdose mortality rate plateaued in 2018 after climbing for 2 decades,4 preliminary 2019 data suggest a return to increasing year-over-year rates.1 Nationally, deaths involving cocaine and other stimulants increased sharply after 2016, including among youth ages 15 to 24.1,5

The overdose crisis is complex and evolving. Public health experts have described it as having occurred in waves.5,6 The first wave, beginning in the early 2000s, was largely driven by increases in prescription opioid-related overdoses, likely fueled by aggressive industry marketing of opioid products.7 Concomitant with a decrease in opioid prescribing, heroin began to supplant prescription opioids during the second wave of the early 2010s. From late 2013 onwards, highly potent fentanyl flooded drug markets and contributed to unprecedented mortality during the third wave. Now, in the fourth wave of the crisis, clinicians, public health experts, and policymakers are grappling with rising overdose fatalities involving stimulants, particularly cocaine and methamphetamine.

Pediatricians and other clinicians caring for youth should be concerned. Approximately 1 in 25 high school students has used cocaine, and 1 in 50 has used methamphetamine.8 Racial inequities are pernicious; previous work has revealed that Black and Latinx youth are significantly less likely to receive timely evidence-based addiction treatment.9 These inequities are critical not only because of the excess risk for overdose without recommended care, but also because youth of color are significantly more likely than white youth to be incarcerated for drug-related charges and to experience lifelong adverse health consequences stemming from criminal justice involvement.

What should also concern clinicians is the exceptional difficulty of treating stimulant use disorder. Whereas opioid use disorder is effectively treated with US Food and Drug Administration–approved medications,10 there are no approved pharmacotherapies for stimulant use disorder, and most behavioral therapies are disappointingly ineffective.11 Similarly, whereas widespread distribution of the opioid overdose reversal agent naloxone in the United States has averted innumerable deaths,12 no comparable antidote exists for stimulants. Preventing stimulant use disorder from developing in the first place remains our best hope for averting downstream harms.

Roehler et al draw much-needed early attention to this worsening public health problem. Further studies are needed. The authors examine overdoses among 15- to 24-year-olds collectively; more granular age data would shed light on the precise times that overdoses are rising during adolescence and young adulthood. Data are also needed on how stimulant overdoses in youth are related to rising fentanyl overdose6 and to polysubstance use more broadly, including use of benzodiazepines and alcohol.13,14 Finally, researchers should take care to identify differences by race and ethnicity to ensure that our clinical and public health responses reduce inequities rather than exacerbate them.15

Researchers should also pursue a greater understanding of which stimulants are involved in the pathway to misuse, addiction, and overdose and whether they are illicit drugs like cocaine and methamphetamine, prescription pills, or both. Treating attention deficient/hyperactivity disorder is not associated with risk for substance-use disorder; clinicians should continue to prescribe stimulants when appropriate.16 Nonetheless, there has been a simultaneous rise in stimulant prescribing,17 misuse among young adults (particularly college students),18 and pharmaceutical industry marketing to pediatricians.19 Understanding whether the widespread availability of prescription stimulants is related to rising overdose rates, or if it is simply coincidental, could inform prescribing guidelines.

In the meantime, pediatricians and other clinicians can take immediate action. They can routinely screen for substance use using a validated tool (eg, Screening to Brief Intervention, https://www.drugabuse.gov/ast/s2bi/; Brief Screener for Tobacco, Alcohol, and other Drugs, https://www.drugabuse.gov/ast/bstad/; Car, Relax, Alone, Forget, Family/Friends, Trouble, https://crafft.org/), counsel on substance use, and refer to addiction treatment when needed.20,21 As respected citizens in their communities, clinicians can advocate for evidence-based prevention programming in schools and other settings. When clinicians prescribe stimulants, they can counsel parents that they should ensure safe, locked storage of medications, which is especially critical given the rising rates of presumably unintentional stimulant overdoses observed in younger ages in the study by Roehler et al. Given that preliminary national 2019 data suggest that overdose rates have once again resumed their climb,1 addressing stimulant misuse and overdose early in the life course is urgent.

Footnotes

    • Accepted October 8, 2020.
  • Address correspondence to Scott E. Hadland, MD, MPH, MS, Boston Medical Center, 801 Albany St, Room 2055, Boston, MA 02119. E-mail: scott.hadland{at}bmc.org
  • Opinions expressed in these commentaries are those of the author and not necessarily those of the American Academy of Pediatrics or its Committees.

  • FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

  • FUNDING: Dr Hadland received grant support from the National Institute on Drug Abuse (K23DA045085, L40DA042434) and the Thrasher Pediatric Fund Early Career Award. Dr Marshall received grant support from the National Institute on Drug Abuse (R01-DA046620).

  • POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

  • COMPANION PAPER: A companion to this article can be found online at www.pediatrics.org/cgi/doi/10.1542/2020-003491.

References

  1. 1.↵
    1. O’Donnell J,
    2. Gladden RM,
    3. Mattson CL,
    4. Hunter CT,
    5. Davis NL
    . Vital signs: characteristics of drug overdose deaths involving opioids and stimulants - 24 states and the District of Columbia, January–June 2019. MMWR Morb Mortal Wkly Rep. 2020;69(35):1189–1197
    OpenUrl
  2. 2.↵
    1. Liu S,
    2. Scholl L,
    3. Hoots B,
    4. Seth P
    . Nonfatal drug and polydrug overdoses treated in emergency departments - 29 states, 2018–2019. MMWR Morb Mortal Wkly Rep. 2020;69(34):1149–1155
    OpenUrl
  3. 3.↵
    1. Roehler DR,
    2. Olsen EO,
    3. Mustaquim D,
    4. Vivolo-Kantor AM
    . Suspected nonfatal opioid and other drug-related overdoses among youth in the US, 2016–2019. Pediatrics. 2020;147(1):2020003491e
    OpenUrl
  4. 4.↵
    1. Wilson N,
    2. Kariisa M,
    3. Seth P,
    4. Smith H IV,
    5. Davis NL
    . Drug and opioid-involved overdose deaths - United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2020;69(11):290–297
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Kariisa M,
    2. Scholl L,
    3. Wilson N,
    4. Seth P,
    5. Hoots B
    . Drug overdose deaths involving cocaine and psychostimulants with abuse potential - United States, 2003–2017. MMWR Morb Mortal Wkly Rep. 2019;68(17):388–395
    OpenUrlPubMed
  6. 6.↵
    1. Gaither JR,
    2. Shabanova V,
    3. Leventhal JM
    . US national trends in pediatric deaths from prescription and illicit opioids, 1999–2016. JAMA Netw Open. 2018;1(8):e186558
    OpenUrl
  7. 7.↵
    1. Hadland SE,
    2. Cerdá M,
    3. Li Y,
    4. Krieger MS,
    5. Marshall BDL
    . Association of pharmaceutical industry marketing of opioid products to physicians with subsequent opioid prescribing. JAMA Intern Med. 2018;178(6):861–863
    OpenUrl
  8. 8.↵
    US Centers for Disease Control and Prevention. YRBSS results. 2020. Available at: https://www.cdc.gov/healthyyouth/data/yrbs/results.htm. Accessed September 11, 2020
  9. 9.↵
    1. Hadland SE,
    2. Wharam JF,
    3. Schuster MA,
    4. Zhang F,
    5. Samet JH,
    6. Larochelle MR
    . Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001–2014. JAMA Pediatr. 2017;171(8):747–755
    OpenUrl
  10. 10.↵
    1. Committee on Substance Use and Prevention
    . Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics. 2016;138(3):e20161893
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Ronsley C,
    2. Nolan S,
    3. Knight R, et al
    . Treatment of stimulant use disorder: a systematic review of reviews. PLoS One. 2020;15(6):e0234809
    OpenUrl
  12. 12.↵
    1. Pitt AL,
    2. Humphreys K,
    3. Brandeau ML
    . Modeling health benefits and harms of public policy responses to the US opioid epidemic. Am J Public Health. 2018;108(10):1394–1400
    OpenUrl
  13. 13.↵
    1. Lembke A,
    2. Papac J,
    3. Humphreys K
    . Our other prescription drug problem. N Engl J Med. 2018;378(8):693–695
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. White AM,
    2. Castle IP,
    3. Hingson RW,
    4. Powell PA
    . Using death certificates to explore changes in alcohol-related mortality in the United States, 1999 to 2017. Alcohol Clin Exp Res. 2020;44(1):178–187
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Jordan A,
    2. Mathis ML,
    3. Isom J
    . Achieving mental health equity: addictions. Psychiatr Clin North Am. 2020;43(3):487–500
    OpenUrl
  16. 16.↵
    1. Humphreys KL,
    2. Eng T,
    3. Lee SS
    . Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry. 2013;70(7):740–749
    OpenUrl
  17. 17.↵
    1. Piper BJ,
    2. Ogden CL,
    3. Simoyan OM, et al
    . Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016. PLoS One. 2018;13(11):e0206100
    OpenUrl
  18. 18.↵
    1. Schulenberg JE,
    2. Johnston LD,
    3. O’Malley PM,
    4. Bachman JG,
    5. Miech RA,
    6. Patrick ME
    . Monitoring the Future National Survey Results on Drug Use 1975–2019: Volume 2, College Students & Adults Ages 19–60. Ann Arbor, MI: Institute for Social Research, The University of Michigan; 2020. Available at: www.monitoringthefuture.org/pubs/monographs/mtf-vol2_2019.pdf. Accessed September 15, 2020
  19. 19.↵
    1. Hadland SE,
    2. Cerdá M,
    3. Earlywine JJ,
    4. Krieger MS,
    5. Anderson TS,
    6. Marshall BDL
    . Analysis of pharmaceutical industry marketing of stimulants, 2014 through 2018. JAMA Pediatr. 2020;174(4):385–387
    OpenUrl
  20. 20.↵
    1. Levy SJ,
    2. Williams JF; Committee on Substance Use and Prevention
    . Substance use screening, brief intervention, and referral to treatment. Pediatrics. 2016;138(1):e20161211
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Steele DW,
    2. Becker SJ,
    3. Danko KJ, et al
    . Brief behavioral interventions for substance use in adolescents: a meta-analysis. Pediatrics. 2020;146(4):e20200351
    OpenUrlAbstract/FREE Full Text
  • Copyright © 2021 by the American Academy of Pediatrics
PreviousNext
Back to top

Advertising Disclaimer »

In this issue

Pediatrics
Vol. 147, Issue 1
1 Jan 2021
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Rising Stimulant Overdoses Among Young People in the United States
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
Rising Stimulant Overdoses Among Young People in the United States
Scott E. Hadland, Brandon D.L. Marshall
Pediatrics Jan 2021, 147 (1) e2020031526; DOI: 10.1542/peds.2020-031526

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Rising Stimulant Overdoses Among Young People in the United States
Scott E. Hadland, Brandon D.L. Marshall
Pediatrics Jan 2021, 147 (1) e2020031526; DOI: 10.1542/peds.2020-031526
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • Comments

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Progress in Helping Children Who are Deaf or Hard of Hearing Achieve Their Potential
  • Is Developmental Screening Enough in High-Risk Populations?
  • Vestibular Disorders in Congenital Cytomegalovirus: A Balancing Act
Show more Commentaries

Similar Articles

  • Journal Info
  • Editorial Board
  • Editorial Policies
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Submit My Manuscript
  • Open Access
  • Reviewer Guidelines
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • AAP.org
  • shopAAP
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
American Academy of Pediatrics

© 2021 American Academy of Pediatrics